Back to results
US 7,622,495 B2Granted
Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
AssigneeNeurim Pharmaceuticals (1991) Ltd.
InventorsTal Peleg-Shulman, Moshe Laudon, Dorah Daily
Life of this patent
Estimating the term…
Abstract
This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3β kinase and/or modulating N-methyl-D-aspartate (NMDA) channel activities for the treatment of neurodegenerative and other disorders.
Claims5
A compound selected from
- (a) N-(4-methylsulfonyl-2-nitrophenyl)-5-methoxytryptamine,
- (b) N-(2-bromo-4-nitrophenyl)-5-methoxytryptamine,
- (c) N-(4-bromo-2-nitrophenyl)-5-methoxytryptamine,
- (d) N-(2-cyano-4-nitrophenyl)-5-methoxytryptamine,
- (e) N-(4-Carboxy-2-nitrophenyl)-tryptamine,
- (f) N-(2-Carboxy-4-nitrophenyl)-tryptamine,
- (g) N-(2-Nitrophenyl)-5-methoxytryptamine,
- (h) N-(4-Carboxy-2-nitrophenyl)-5-methoxytryptamine,
- (i) N-(2-Carboxy-4-nitrophenyl)-5-methoxytryptamine,
- (j) N-(2-cyano-4-nitrophenyl)-tryptamine,
- (k) N-(2-nitro-4-bromophenyl)-tryptamine,
- (l) N-(3,4-dicyanophenyl)-tryptamine, and
- (m) N-(3,4-dicyanophenyl)-5-methoxytryptamine.
10 more elements
Dependencies are inferred from the claim text.